Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL29264273 | 0.98 | DNM1 (0.51) | DNM1EPHX1KDM4EEPHX2PAOX | |
| Hydrochloric Acid SCHEMBL218974 | 0.98 | DNM1 (0.51) | DNM1EPHX1KDM4EEPHX2PAOX | |
| Hydrochloric Acid SCHEMBL15878572 | 0.98 | DNM1 (0.51) | DNM1EPHX1KDM4EEPHX2PAOX | |
| Iodomethane SCHEMBL4824562 | 0.96 | DNM1 (0.50) | DNM1EPHX1KDM4EEPHX2PAOX | |
| SCHEMBL13670125 | 0.94 | EPHX1 (0.52) | DNM1EPHX1KDM4EEPHX2PAOX | |
| SCHEMBL36169 | 0.91 | DNM1 (0.55) | DNM1EPHX1KDM4EPAOXHPGD | |
| Hydrochloric Acid SCHEMBL10730965 | 0.89 | DNM1 (0.53) | DNM1EPHX1KDM4EPAOXHPGD | |
| SCHEMBL20972405 | 0.88 | EPHX1 (0.63) | DNM1EPHX1KDM4E | |
| SCHEMBL11149127 | 0.87 | EPHX1 (0.58) | DNM1EPHX1KDM4EPAOXHPGD | |
| SCHEMBL3633166 | 0.87 | DNM1 (0.48) | DNM1EPHX1KDM4EEPHX2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 434 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360161-A1 | CHEMICALLY MODIFIED HEPARIN | IHP THERAPEUTICS INC (US) | 2025-11-27 | — | — | US | claimed |
| US-20250353936-A1 | CHEMICALLY MODIFIED HEPARIN | IHP THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | claimed |
| WO-2025122010-A1 | A METHOD FOR PURIFYING A MODIFIED GELATIN | SENTRYX B.V. (NL) | 2025-06-12 | — | — | WO | claimed |
| EP-4536248-A1 | CHEMICALLY MODIFIED HEPARIN | IHP Therapeutics Inc. (US) | 2025-04-16 | — | — | EP | claimed |
| EP-4536745-A1 | CHEMICALLY MODIFIED HEPARIN | IHP Therapeutics Inc. (US) | 2025-04-16 | — | — | EP | claimed |
| CN-119325383-A | Chemically modified heparin | IHP治疗公司 | 2025-01-17 | — | — | CN | claimed |
| CN-119301188-A | Chemically modified heparin | IHP治疗公司 | 2025-01-10 | — | — | CN | claimed |
| EP-4469459-A1 | PROCESS FOR PREPARING CRYSTALLINE SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE | Zaklady Farmaceutyczne Polpharma S.A. (PL) | 2024-12-04 | — | — | EP | claimed |
| CN-117723691-A | Detection method of 1- [3- (dimethylamino) propyl ] -3-ethylurea | 珠海优泽生物科技有限公司 | 2024-03-19 | — | — | CN | claimed |
| CN-115406979-B | High performance liquid chromatography analysis method for residual 1-ethyl [3- (dimethylamino) -propyl ] -carbodiimide hydrochloride | 陕西慧康生物科技有限责任公司 | 2024-02-27 | — | — | CN | claimed |
| EP-1237849-A1 | ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | UNIVERSITY COLLEGE LONDON (GB) | 2002-09-11 | — | — | EP | claimed |
| EP-0679892-B1 | Microparticle immunoassay reagents, sensitive and specific immunoassay reagents and immunoassay methods using these reagents | SERADYN INC (US) | 2002-08-28 | — | — | EP | claimed |
| EP-0667529-B1 | Non-specific reaction suppressor for immunoassays | SERADYN INC (US) | 2002-06-05 | — | — | EP | claimed |
| WO-2001032604-A1 | ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | UNIVERSITY COLLEGE LONDON (GB) | 2001-05-10 | — | — | WO | claimed |
| CN-1122913-A | Particulate immunoassay agent, sensitive and specific immunoassay agent, and immunoassay method using these immunoassay agents | MITSUBISHI CHEM CORP (JP) | 1996-05-22 | — | — | CN | claimed |
| US-5506151-A | IMMUNOASSAY | MITSUBISHI KASEI CORPORATION (JP) | 1996-04-09 | — | — | US | claimed |
| US-5486479-A | Buffer for immunoassay, kit including same and immunoassay method using said buffer | MITSUBISHI CHEMICAL CORPORATION (JP) | 1996-01-23 | — | — | US | claimed |
| EP-0679892-A1 | Microparticle immunoassay reagents, sensitive and specific immunoassay reagents and immunoassay methods using these reagents | Mitsubishi Chemical Corporation (JP) | 1995-11-02 | — | — | EP | claimed |
| CN-1111016-A | Non-specific reaction inhibitor | MITSUBISHI CHEM CORP (JP) | 1995-11-01 | — | — | CN | claimed |
| EP-0667529-A2 | Non-specific reaction suppressor for immunoassays | MITSUBISHI CHEMICAL CORPORATION (JP) | 1995-08-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250360161-A1 | CHEMICALLY MODIFIED HEPARIN | SI, HPSE, FABP2 | DNM1 4456/4885EPHX1 824/4885KDM4E 3999/4885 |
| US-20250353936-A1 | CHEMICALLY MODIFIED HEPARIN | FABP2, HABP2, SI | DNM1 4154/4885EPHX1 1049/4885KDM4E 1282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.